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SURVIVAL for children is significantly higher than for 
adults after liver transplantation (LTx).l A center· 
specific 20·year retrospective analysis of all pediatric trans· 
plant recipients was implemented to determine patient and 
graft survival, graft survival, and differences in survival 
related to immunosuppressive protocols. 
MATERIALS AND METHODS 
From March 1981 to April 1998, 808 children received liver 
transplants at the Children's Hospital of Pittsburgh. All patients 
were followed until March 2001, with a mean follow·up of 12.2 ::<:: 
3.9 years (median = 12.6; range = 2.9 to 20). There were 405 
female (50.2%) and 403 male (49.8%) pediatric recipients. The 
mean age at transplant was 5.3 ::': 4.9 years (mean = 3.3; range 0.04 
to 17.95) with 285 children (25.3%) being less than 2 years of age 
at transplant. Cyclosporine (CsA)-based immunosuppression was 
used prior to November 1989 in 482 children (50.7%) and the 
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subsequent 326 recipients (40.3%) were treated with tacrolimus-
based immunosuppression. 
RESULTS 
Patient Survival 
Overall patient survival at 1, 5, 10, 15, and 20 years was 
77.1 %, 72.6%, 69.4%, 65.8%, and 64.4%, respectively (Fig 
1). A significant difference in survival was seen in CsA-
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Fig 1. Patient survival under cyclosporine and tacrolimus immunosuppression. 
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Fig 2. Overall morality rate over time under cyclosporine and tacrolimus immunosuppression. 
based immunosuppression (71.2%, 68.1%, 65.4%, and 
61 %) versus tacrolimus-based immunosuppression (85.8%, 
84.7%,83.3%, and 82.9%) at 1, 3,5, and 10 years, respec-
tively (P = .0001) (Fig 2). The maximum difference in the 
risk of death was observed in the first 3 months posttrans-
plant, 22.8% under esA versus 9.5% under tacrolimus. 
After 3 months, the survival at 10 years was 78.6% under 
esA versus 91.5% under tacrolimus, a difference of 12.9%. 
Causes of Death 
A total of 258 children (32%) died during the follow-up 
period, with 55.4% of deaths occurring within the first 3 
months posttransplant. Of the mortalities, 203 recipients 
received esA-based immunosuppression, and 55 recipients 
were treated with tacrolimus. The most common cause of 
death was infection (43%). The mean annual death rate 
beyond 2 years posttransplant was 0.47% with the mean 
annual death rate for patients receiving tacrolimus-based 
immunosuppression being significantly lower than those 
receiving esA-based immunosuppression (0.14% vs 0.8%; 
P = .001). The annual death rate for patients under esA 
and tacrolimus-based immunosuppression is shown in Fig 2. 
The difference in the death rate between the immunosup-
pressive protocols was observed at all time points. The 
cumulative death rate at 1, 3, and 12 months posttransplant 
under esA was 16.3%, 22.6%, and 28.8%, respectively, and 
for tacrolimus-treated patients was 6.4%, 9.5%, and 14%, 
respectively. 
Graft Survival 
Patient deaths or retransplantations were considered as 
graft loss. Graft survival at 1. 5. 10, 15. and 20 years was 
(16,6G'O. 60%. 57%. 52.3%. and 37.9%, respectivelv. Graft 
survival LInder CsA versus tacrolimus-based immunosup-
rresslOn was similar to patient survival With a highlv signif-
Icant difference \ P = .0001) at 12 years posttransplant. 
Retransplantation 
Two hundred three children (25.1 %) required a second 
liver transplant. Additionally, 40 children required a third 
graft, six received four grafts, and one child received five 
liver transplants. All seven children who received four or 
more grafts died. Hepatic artery thrombosis was the most 
common indication for a second allograft under both esA-
and tacrolimus-based immunosuppression, with an inci-
dence of 33.4% (n=68) of all retransplantations. The 
second most common reason for retransplantation was 
rejection, both acute and chronic, with 54 patients (26.6%) 
requiring another graft. Retransplantation was required in 
six patients (2.9%) with acute rejection and 46 patients 
(22.6%) with chronic rejection. Interestingly, all retrans-
plantations for acute or chronic rejection were performed 
in patients who were treated with esA-based immunosup-
pression and none under tacrolimus. 
Primary nonfunction was the third most common indica-
tion for retransplantation and was seen in 34 patients 
(16.7%). Of these patients, 19 (9.3%) were treated with 
esA and 15 (7.3%) were treated with tacrolimus. Addi-
tional reasons for retransplantation included biliary stric-
ture, posttransplantation lymphoproliferative disorder, and 
others. 
DISCUSSION 
A 20-year overall actuarial patient survival of 64..+% is 
reported here. representing the largest pediatric liver trans-
plant experitnce with the longest follow-up from a singk 
center. The most significant factor affecting survival in this 
experience was a change in immunosuppressive protocols 
from CsA-based immunosuppression in the 1980s. with a 
survival of hI % at 10 years. to tacrolimus-based immuno-
suppression resulting in an R3% survival at 10 years. This 
analysis reports the almost complete absence of graft loss 
from either acute or chronic rejection under tacroJimus. 
which is remarkable conSIdering the incidence under esA is 
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11 S in a 20-year follow-up. Over u decade ago. observa-
tions from this institutIon supported the findings of a 
reduced rate of acute rejection as well as a decreased 
severity of rejection in patients receiving tacrolimus. 2.3 
Additionally. the ability of tacrolimus to reverse acute and 
chronic rejection and act as a rescue agent for patients 
failing treatment with CsA provided a better understanding 
of the process of rejection and its treatmen t as well as the 
clinical limits of failure. At this institution, nearly 25% of 
children under CsA-based immunosuppression have been 
converted to tacrolimus with many of the grafts rescued 
from acute and chronic rejection during the last decade. 4 
Similar advantages of tacrolimus in pediatric transplanta-
tion have been published from our center and by others5 --7 
Nearly 80% of pediatric patients are now maintained on 
only low-dose tacrolimus.K The virtual absence of chronic 
rejection in adult liver transplant recipients following a 
review of over 5000 liver biopsies from more than 1200 
patients with a mean follow-up of 6 years has been previ-
ously reported9 Hepatitis Band C viruses, primary biliary 
cirrhosis, autoimmune hepatitis, and primary sclerosing 
cholangitis were found to be risk factors for the develop-
ment of chronic rejection after liver transplantation. Fortu-
nately, these liver diseases as indications for transplantation 
are extremely rare in the pediatric population. Chronic 
rejection in pediatric liver transplant recipients is usually a 
result of treatment for life-threatening infection PTLD or 
noncompliance. 
CONCLUSION 
The 20-year actuarial survival for pediatric liver transplant 
recipients is 64% in a series of 808 children. Infection 
1957 
remains thc most common cause of death. Retransplanta-
tion is most commonly indicated for hepatic artery throm-
bosis and primary nonfunction. Survival following the in-
troduction of tacrolimus-based immunosuppression has 
increased hy 14 to 21 % at I year (85% vs 71.2% I and 12 
years (82.9% vs 61 %) posttransplant. The incrcased sur-
vival rate of our program may reflect improvements in 
surgical techniques. bettcr donor and recipient selection, 
and advances in posttransplant medical management. How-
ever. in our experience. increased survival can be attributed 
to the almost total absence of graft loss due to acute or 
chronic rejection in up to a 12-year follow-up, which reflects 
the immunologic advantage of tacrolimus-bK~sed immuno-
suppression. 
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